Penumbra Inc (PEN) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Penumbra Inc  (NYSE: PEN)

Select the Financial Report: Select the Period:


Description of Penumbra Inc's Business Segments


Penumbra Inc. is a pioneering medical technology company that specializes in innovative solutions aimed at addressing some of the most complex and challenging medical conditions. The companys diverse portfolio includes multiple segments, each targeted toward specific areas of healthcare delivery, focusing primarily on improving diagnosis, treatment, and patient outcomes across critical medical disciplines such as neurology, vascular health, and cardiology.

Segments

1. Neuron
In the Neuron segment, Penumbra develops advanced products designed specifically for the diagnosis and treatment of neurovascular diseases. These conditions often include critical issues such as cerebral aneurysms, hemorrhagic strokes, and ischemic strokes. Key products in this segment include:

- Penumbra System: This represents the flagship product line that utilizes innovative mechanical thrombectomy technology to remove blood clots from the brain, thus significantly improving patient outcomes post-stroke.
- Coil 400: An embolic coil specifically designed for intracranial aneurysms, providing enhanced performance in deploying in various anatomical scenarios.
- Broughton Embolic Coil: A new addition aimed at facilitating the safe and effective treatment of intracranial aneurysms while minimizing complications.

The innovations offered by this segment drastically enhance treatment efficacy and offer healthcare providers tools to mitigate potential damage from life-threatening neurological emergencies.

Vascular
The Vascular segment focuses on peripheral vascular diseases and includes products designed for conditions such as deep vein thrombosis (DVT) and pulmonary embolisms. Important offerings in this segment comprise:

- Penumbra System with Indigo Separator: A valuable device that employs suction and separation techniques to facilitate the removal of thrombus effectively while preserving vessel integrity.
- Ruby Coil System: This is tailored for embolization procedures, providing enhanced delivery and deployment features compared to traditional coils.
- 3D Revascularization Device: An innovative solution aimed at restoring blood flow in peripheral arteries, improving overall limb perfusion and reducing the risk of tissue loss.

These products streamline interventional procedures, offering healthcare providers efficient options for treating various acute and chronic vascular conditions.

Cardiac
The Cardiac segment incorporates technologies aimed at treating a range of heart-related conditions, including cardiac arrhythmias and heart failure. Noteworthy products include:

- TRUE Flow Infusion System: Designed for delivering fluid and medications in a precise manner during cardiovascular procedures, enhancing patient safety and treatment effectiveness.
- Cobra CTO Devices: These devices are crucial for treating chronic total occlusions, facilitating access to blocked arteries and improving perfusion.

The cardiac offerings aim to empower healthcare providers in managing complex cardiac conditions, contributing to improved patient care and recovery.

Products and Services

1. Neuro Interventional Products
Penumbras Neuro Interventional products are at the forefront of stroke treatment innovations. These products are skillfully designed to support physicians in effectively managing strokes and other neurovascular crises, leading to better patient prognoses and recovery outcomes.

Peripheral Vascular Products
The Peripheral Vascular product line provides essential tools for managing vascular diseases, facilitating minimally invasive procedures that significantly lessen patient discomfort and recovery time while maximizing clinical effectiveness.

Cardiac Intervention Products
The Cardiac Intervention products reflect Penumbras ongoing commitment to enhancing cardiovascular care, providing tools that facilitate intricate diagnostics and treatments in a range of cardiac conditions.

Clinical Training and Education
Recognizing the importance of proper application of its technologies, Penumbra offers extensive training and educational initiatives. These programs are essential for healthcare providers, ranging from basic to advanced training, ensuring optimal use of the products and enhancing patient care.

Technical Support
Penumbra provides round-the-clock technical support for its healthcare partners. This service is crucial for promptly resolving issues and enabling seamless integration of Penumbra products into clinical routines, thereby boosting the confidence of practitioners using these advanced technologies.

Conclusion
In summary, Penumbra Inc. delivers a broad spectrum of advanced products and services targeted at improving the diagnosis and treatment of critical medical conditions affecting the neuro, vascular, and cardiac systems. Through its innovative technology, comprehensive training, and unwavering support, the company is dedicated to enhancing patient outcomes and ensuring healthcare providers are equipped to deliver the highest standard of care.


Composition of Penumbra Inc Revenues by Segments

 
United States    79.09 % of total Revenue
International    20.91 % of total Revenue
Thrombectomy    67.75 % of total Revenue
Embolization and Access    32.25 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
United States 296.39 79.09 %
International 78.37 20.91 %
Thrombectomy 253.92 67.75 %
Embolization and Access 120.84 32.25 %
Total 374.76 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
United States 15.39 % -
International 16.48 % -
Thrombectomy 12.08 % -
Embolization and Access 23.82 % -
Total 15.62 % -




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total 32.58 8.69 %




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total -16.93 % -




Annual Report on Penumbra Inc Divisions, Sales by Country

 
United States   United States Segment contribution to total sales 77.78 % of total Revenue
International   International Segment contribution to total sales 22.22 % of total Revenue
Thrombectomy   Thrombectomy Segment contribution to total sales 67.53 % of total Revenue
Embolization and Other   Embolization and Other Segment contribution to total sales 32.47 % of total Revenue


Twelve months ended 2025
PEN s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
United States 1,091.76 77.78 %
International 311.90 22.22 %
Thrombectomy 947.92 67.53 %
Total 1,403.67 100 %
Embolization and Other 455.75 32.47 %


Twelve months ended 2025
PEN s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total 177.69 12.66 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
United States 21.03 % -
International 6.62 % -
Thrombectomy 16.24 % -
Total 17.5 % 1168.11 %
Embolization and Other 20.21 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.